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Phe Implications of Blood
ransfusions for Patients With
on–ST-Segment Elevation Acute Coronary Syndromes
esults From the CRUSADE National Quality Improvement Initiative
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atthew T. Roe, MD, MHS, FACC,* Ralph G. Brindis, MD, MPH, FACC,†
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urham and Chapel Hill, North Carolina; Cincinnati, Ohio; and San Francisco, California
OBJECTIVES In a large contemporary population of patients with non–ST-segment elevation acute
coronary syndromes (NSTE ACS), we sought to describe blood transfusion rates (overall and
in patients who did not undergo coronary artery bypass grafting [CABG]), patient
characteristics and practices associated with transfusion, variation among hospitals, and
in-hospital outcomes in patients receiving transfusions.
BACKGROUND The use of antithrombotic agents and invasive procedures reduces ischemic complications but
increases risks for bleeding and need for blood transfusion in patients with NSTE ACS.
METHODS We evaluated patient characteristics and transfusion rates in the overall population (n 
85,111) and determined outcomes and factors associated with need for transfusion in a
subpopulation of patients who did not undergo CABG (n 74,271) from 478 U.S. hospitals
between January 1, 2001, and March 31, 2004.
RESULTS A total of 14.9% of the overall and 10.3% of the non-CABG population underwent
transfusion during their hospitalization. Renal insufficiency and advanced age were strongly
associated with the likelihood of transfusion. Interhospital transfusion rates varied significantly.
Non-CABG patients who received transfusions had a greater risk of death (11.5% vs. 3.8%)
and death or reinfarction (13.4% vs. 5.8%) than patients who did not undergo transfusion.
CONCLUSIONS Transfusion is common in the setting of NSTE ACS, and patients who undergo transfusion
are sicker at baseline and experience a higher risk of adverse outcomes than their
nontransfused counterparts. Given the wide variation in transfusion practice, further efforts to
understand patient and process factors that result in bleeding and need for transfusion in
NSTE ACS are needed. (J Am Coll Cardiol 2005;46:1490–5) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.072College of Cardiology Foundation
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tn recent years, significant advances have been made in the
iagnosis, risk stratification, and therapy of non–ST-
egment elevation acute coronary syndromes (NSTE ACS)
1–3). A key part of this management strategy involves
ombining multiple antiplatelet and anticoagulation agents
long with invasive therapy in high-risk patients with
STE ACS (2,3). Although these therapeutic modalities
ave been shown to reduce recurrent ischemic events in
atients with NSTE ACS (4–7), they also increase the risks
or bleeding and need for blood transfusion (7,8). Reported
ates of major bleeding and transfusion from NSTE ACS
linical trial populations range from 1% to 9% (9–12).
From the *Division of Cardiology and Duke Clinical Research Institute, Duke
niversity Medical Center, Durham, North Carolina; †Kaiser-Permanente San
rancisco Medical Center, San Francisco, California; ‡University of Cincinnati
chool of Medicine, Cincinnati, Ohio; and the §Division of Cardiology, University
f North Carolina, Chapel Hill, North Carolina. The CRUSADE trial is funded by
illennium Pharmaceuticals Inc., and Schering-Plough Corp. Bristol-Myers Squibb/
anofi Pharmaceuticals Partnership provides an unrestricted grant in support of the
rogram. Drs. Roe, Gibler, Ohman, and Peterson have served either on speakers’
ureaus or have received research grants from the sponsors of the CRUSADE trial.f
Manuscript received April 21, 2005; revised manuscript received June 21, 2005,
ccepted June 27, 2005.owever, extrapolation of these bleeding and transfusion
ates from trial to community practice is challenging because
rial populations tend to be younger and healthier (13).
dditionally, patients within trials usually are treated ac-
ording to rigorously defined protocols that influence drug
osing and combinations.
The Can Rapid risk stratification of Unstable Angina
atients Suppress Adverse Outcomes With Early Imple-
entation of the American College of Cardiology/
merican Heart Association Guidelines (CRUSADE) Na-
ional Quality Improvement Initiative includes a broad
ampling of U.S. practices, providing the ideal database in
hich to explore the use of blood transfusion in the
ommunity setting. The purpose of this analysis is to
escribe: 1) blood transfusion rates (both overall and those
nrelated to coronary artery bypass grafting [CABG] sur-
ery; 2) patient characteristics and care practices associated
ith transfusion; 3) variation in the use of transfusion across
ospitals; and 4) in-hospital outcomes in patients receiving
ransfusions compared with those who do not during care
or NSTE ACS in the community.
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he CRUSADE initiative is an ongoing database of pa-
ients with high-risk NSTE ACS that have been admitted
o U.S. hospitals since November 2001. The hospitals
articipating in the CRUSADE initiative are diverse in
heir size, teaching status, capacity, and region. Relative to
ational averages, the CRUSADE hospitals are larger and
ore likely to have catheterization laboratories and surgical
apabilities.
nclusion criteria. Criteria for participation in the database
nclude symptoms referable to myocardial ischemia lasting
10 min combined with positive cardiac biomarkers or
schemic ST-segment electrocardiograph changes (ST-
egment depression or transient ST-segment elevation).
atients are ineligible if they transfer to a CRUSADE
ospital 24 h after their last ischemic symptoms.
atient population. The current population was derived
rom the 98,571 patients enrolled in CRUSADE initiative
rom January 1, 2001, to March 31, 2004. Patients were
neligible for this analysis if they were transferred to another
ospital (n 12,529) or had incomplete data on transfusion
tatus (n  931). Because of the different implications of
ransfusion in the setting of CABG, we excluded patients
ho underwent CABG during their hospitalization (n 
0,840) for analyses of factors associated with or outcomes
elated to use of transfusion. Thus, the overall sample
ncluded 85,111 patients, and the non-CABG sample
ncluded 74,271 patients enrolled in 478 hospitals.
ata collection. Hospitals participating in the CRUSADE
nitiative collect detailed processes of care and in-hospital
utcomes data through retrospective chart review using a
tandardized questionnaire. The institutional review board
f each institution approves participation in the CRU-
ADE initiative. Data are collected anonymously during
he initial hospitalization, and because no patient identifiers
re collected, individual informed consent is not required.
ata collected include demographic and clinical informa-
ion, medical history, medical therapies and associated
ajor contraindications, use of acute medications (within
4 h of presentation), use and timing of invasive cardiac
rocedures, laboratory results, in-hospital outcomes, physi-
ian and hospital characteristics, and discharge medications
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CHF  congestive heart failure
CRUSADE  Can Rapid Risk Stratification of Unstable
Angina Patients Suppress Adverse
Outcomes with Early Implementation of
the American College of Cardiology/
American Heart Association Guidelines
MI  myocardial infarction
NSTE ACS  non–ST-segment elevation acute coronary
syndromesnd interventions. cata definitions. Blood transfusion is defined as any
onautologus transfusion of either whole blood or packed
ed blood cells. Renal insufficiency is defined by serum
reatinine2.0 mg/dl, creatinine clearance30 ml/min, or
he need for renal dialysis. Hypertension is defined as
ystolic blood pressure 140 mm Hg, diastolic blood
ressure 90 mm Hg on repeated measurements, or hyper-
ension chronically treated with antihypertensive medica-
ions. Signs of congestive heart failure (CHF) are indicated
y exertional dyspnea, orthopnea, shortness of breath, la-
ored breathing, fatigue at either rest or with exertion, rales
reater than one-third of the lung fields, elevated jugular
enous pressure, S3 gallop, or pulmonary congestion on
-ray film believed to represent cardiac dysfunction. Addi-
ional clinical definitions are available on the CRUSADE
eb site (14).
omparisons. Baseline patient characteristics were grouped
ccording to the occurrence of in-hospital transfusion. Then,
he proportion of patients undergoing transfusion was
ompared at the hospital level among the overall population
n  85,111) and the non-CABG subpopulation (n 
4,271). In addition, the use of transfusion in the overall
nd non-CABG subpopulation by patient age groups was
ompared. Finally, the relationship between the number of
ntithrombotic agents used in the acute setting (e.g., hep-
rin, glycoprotein IIb/IIIa inhibitors, aspirin, clopidogrel)
nd transfusion was determined by patient age group for the
on-CABG subpopulation.
tatistical analysis. Continuous variables were reported as
edians and 25th and 75th percentiles, and categorical
ariables were reported as percentages. To test for inde-
endence of transfusion status and in-hospital outcomes,
ilcoxon rank sum tests were used for continuous variables
nd chi-square tests were used for categorical variables.
ultivariate models were used to determine the factors
ssociated with transfusion, and relationship between trans-
usion and in-hospital outcomes. For the first analysis, a
tepwise approach, including a list of variables, was used to
stablish the factors that were associated with blood trans-
usion. For the second analysis, the model controlled for a
tandard list of factors. Candidate variables included in the
odel included patient demographics, (such as age, gender,
ody mass index, race), cardiac risk factors (such as family
istory of coronary artery disease, hypertension, diabetes,
urrent/recent smoker, hypercholesterolemia), medical co-
orbidities (such as renal insufficiency, previous myocardial
nfarction [MI], previous percutaneous coronary interven-
ion, previous CABG, previous CHF, previous stroke),
resenting characteristics (such as ST-segment depression,
T-segment elevation, positive cardiac marker, signs of
HF at presentation, heart rate, systolic blood pressure),
nd socioeconomic status (such as insurance status). Because
atients within a hospital are more likely to be similar,
eneralized estimating equations were used to adjust for
orrelations among clustered responses (i.e., within hospital
orrelations) (15).
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Blood Transfusions in Non–ST-Segment Elevation ACS October 18, 2005:1490–5A p value of0.05 was considered significant for all tests.
ll analyses were performed using SAS software (versions
.2, SAS Institute, Cary, North Carolina).
ESULTS
ransfusion. Blood transfusion during NSTE ACS hos-
italization occurred in 14.9% of the overall population and
0.3% of the non-CABG subpopulation (Fig. 1). The
ercentage of patients who received a transfusion across
ospitals demonstrated a bell-shaped curve (Fig. 1). Al-
hough 30% of U.S. hospitals transfused more than 20% of
heir NSTE ACS population, 15% transfused less than 5%.
atients receiving transfusions were more likely to be
dmitted to larger hospitals (median 397 vs. 380 beds) and
cademic teaching hospitals (33.6% vs. 29.4%) and less
ikely to have a cardiologist as their attending physician
52.5% vs. 59.5%) compared with patients who did not
ndergo transfusion (Table 1). The median (25th, 75th
ercentile) number of units transfused per patient was 2.0
2.0, 3.0) among non-CABG patients and 2.0 (2.0, 4.0) for
he overall population.
atients receiving transfusions. The likelihood of trans-
usion, overall and for non-CABG patients, increased lin-
arly with patient age (Fig. 2). Although patients 55 years
f age rarely required a transfusion (8% overall, 3% non-
ABG), it was not at all uncommon for patients 75 years
o receive transfusions (19% overall, 14% non-CABG).
atients who required a transfusion were older than those
ho did not (median age 73 vs. 67 years; Table 1). Along
ith being older, patients receiving transfusions also were
ore likely to be women (47% vs. 39%), have a smaller body
ass index, and be more commonly covered by Medicare
nsurance (49% vs. 38%) than nontransfused patients.
ransfused patients also had more comorbidity, including
ypertension (75% vs. 68%), diabetes (41% vs. 31%), CHF
24% vs. 18%), and renal insufficiency (24% vs. 12%) than
ontransfused patients (Table 1). Transfused patients also
igure 1. Transfusion by age group for non-coronary artery bypass grafting
CABG) and overall population. Use of transfusion by age group among
he overall population (hatched bars) and the subset excluding patientso
ho underwent coronary artery bypass grafting during hospitalization
solid bars).ere sicker at presentation, with more frequent signs of
HF (33% vs. 21%), higher heart rates (86 vs. 82 beats/
in), and lower systolic blood pressures (141 vs. 145 mm
g) than nontransfused patients. Transfused patients were
dmitted with lower baseline hematocrit values than non-
ransfused patients (median hematocrit 35% vs. 41%) and
ad lower nadir hematocrit values as well (median hemat-
crit 26% vs. 36%). Treatment variables further interacted
ith patient factors like age to determine the risk of
ransfusion. As shown in Figure 3, patients age 75 years
eceived multiple antiplatelet and antithrombin agents with-
able 1. Patient Characteristics by Blood Transfusion Status in
verall Population
Demographics
Blood
Transfusion
(n  12,724)
No Blood
Transfusion
(n  72,387)
opulation 14.9 85.1
ge, yrs* 73 (63, 80) 67 (55, 78)
ge group, yrs
55 10.6 22.8
55–64 17.9 21.2
65–74 27.2 22.0
75 44.3 34.0
MI, kg/m2* 27.0 (23.7, 31.0) 27.7 (24.3, 31.9)
emale gender 47.1 39.2
hite race 79.1 80.2
nsurance type
HMO/private insurance 39.0 45.6
Medicare 48.7 38.2
Medicaid 7.0 8.2
edical history
Hypertension 74.6 68.4
Diabetes mellitus 41.1 31.3
Current/recent smoker 21.6 28.1
Dyslipidemia 47.6 47.2
Renal insufficiency† 23.9 12.3
Previous MI 30.7 30.8
Previous PCI 19.3 21.8
Previous CABG 17.2 21.0
Previous CHF 24.1 17.8
Previous stroke 13.5 10.5
resenting characteristics
Signs of CHF 32.6 21.1
Heart rate, beats/min* 86 (73, 103) 82 (69, 97)
Systolic blood pressure,
mm Hg*
141 (119, 164) 145 (124, 165)
ST-segment depression 43.4 36.2
Troponin elevation 92.5 88.7
Baseline hematocrit*‡ 35 (31, 39) 41 (37, 44)
Nadir hematocrit*‡ 26 (24, 26) 35 (31, 39)
ospital features
Number of beds* 397 (281, 536) 380 (265, 524)
Academic teaching hospital 33.6 29.4
Cared for by cardiologist 52.5 59.5
ata are presented as percentages except as indicated. *Presented as median (25th,
5th percentiles); †renal insufficiency was defined by serum creatinine 2.0 mg/dl,
reatinine clearance 30 ml/min, or need for renal dialysis; ‡hematocrit values from
atients enrolled since November 2003 (n 18,547). All p values are0.0001, except
or previous MI and dyslipidemia, where both are not significant.
BMI  body mass index; CABG  coronary artery bypass grafting; CHF 
ongestive heart failure; HMO health maintenance organization; MImyocardial
nfarction; PCI  percutaneous coronary intervention.ut increasing their risk of transfusion, whereas patients age
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October 18, 2005:1490–5 Blood Transfusions in Non–ST-Segment Elevation ACS75 years experienced an increased risk in transfusion when
iven three or more antithrombotic agents.
actors associated with transfusion. Renal insufficiency
as the most powerful predictor of transfusion even after
djusting for factors known to affect renal function, such as
ge, body mass index, and female gender (Table 2). Ad-
anced patient age remained strongly associated with an
ncreasing likelihood for transfusion after accounting for
ther age-associated clinical factors in the model. The
argest odds ratio for transfusion was in patients75 year of
ge, who had a three-fold higher likelihood of transfusion
han patients 55 years old, followed by patients age 65
ears. Presenting characteristics, such as positive troponins,
lectrocardiogram changes, heart rate, and signs of CHF,
lso were explanatory in predicting the need for transfusion.
fter considering patient factors, the use of invasive care,
ither catheterization or percutaneous coronary interven-
ion, did not contribute to the likelihood of transfusion.
atient outcomes. Patients who received transfusions had
onger hospital stays than those who did not (median [25th,
5th percentile] of 7 days [5.0, 11.0] vs. 4 days [2.0, 5.0],
igure 2. Transfusion practices across hospitals. Distribution of hospitals
ccording to the percent of their overall (hatched bars) and non-coronary
rtery bypass grafting (CABG) population (solid bars) that underwent
ransfusion.
igure 3. Age and transfusion as a function of the number of antithrombin
nd antiplatelet agents used. Acute (24 h) agents considered include: 1)
spirin or clopidogrel, 2) unfractionated heparin, 3) low molecular weight
eparin, and 4) glycoprotein IIb/IIIa inhibitors. Rate of transfusionN
isplayed by patient age and number of agents delivered during hospital
tay.espectively). Transfused patients also had a higher absolute
ate of death (11.5% vs. 3.8%) and of death or MI combined
13.4% vs. 5.8%) compared with nontransfused patients
Table 3). The higher rate of death and MI among patients
eceiving blood transfusions remained significant after ad-
ustment for a comprehensive list of patient and hospital
haracteristics. After adjustment, patients undergoing trans-
usion remained 67% more likely to die and 44% more likely
o experience either death or MI than those who did not
ndergo transfusion during their care.
ISCUSSION
n the community setting, blood transfusions frequently are
iven during the care of patients with NSTE ACS. Patients
ith advanced age or renal dysfunction are at greatest risk,
articularly when treated simultaneously with multiple an-
ithrombotic agents. Although cause and effect cannot be
stablished in an observational analysis, our study demon-
trates an adverse association between transfusion and out-
omes that persists after adjusting for clinical characteristics.
he wide variation in transfusion rates across hospitals
uggests that clarification is needed regarding the causes of
leeding, as well as the appropriate triggers and beneficial
ses of transfusion in the setting of NSTE ACS.
ransfusion comparisons. The transfusion rates reported
n the CRUSADE initiative are higher than from published
able 2. Factors Associated with Blood Transfusion
Variable
Adjusted OR
(95% CI)
Chi
Square
enal insufficiency* 2.43 (2.29–2.58) 835.5
ystolic BP (per 10 mm Hg drop) 1.08 (1.07–1.09) 288.1
emale gender 1.51 (1.43–1.60) 202.2
iabetes mellitus 1.42 (1.35–1.50) 175.8
atient age (vs. 55 yrs)
75 yrs 2.98 (2.62–3.39) 102.9
65–75 yrs 2.58 (2.28–2.91)
55–64 yrs 1.52 (1.37–1.68)
igns of CHF 1.43 (1.34–1.53) 109.1
eart rate (per 10 beats/min increase) 1.05 (1.04–1.07) 94.2
ositive cardiac markers 1.73 (1.55–1.94) 91.1
T-segment depression (vs. neither) 1.46 (1.37–1.55) 84.1
ransient ST-segment elevation
(vs. neither)
1.22 (1.10–1.37)
MI (per 5-U reduction) 1.08 (1.05–1.10) 36.2
nsurance type (vs. HMO/private)
Medicaid 1.55 (1.37–1.75) 33.8
Medicare 1.07 (1.00–1.15)
Self/none 0.98 (0.86–1.12)
o family history of CAD 1.14 (1.07–1.21) 18.8
ypertension 1.13 (1.07–1.21) 16.6
bsence of dyslipidemia 1.07 (1.02–1.13) 7.1
onwhite versus white 1.10 (1.02–1.19) 6.6
revious stroke 1.08 (1.01–1.15) 5.3
etermined using non-CABG subpopulation. All p values are 0.0001 except for
bsence of dyslipidemia (p  0.008), nonwhite versus white (p  0.01), and previous
troke (p  0.02). *Serum creatinine 2.0 mg/dl.
BP  blood pressure; CAD  coronary artery disease; CI  confidence interval;
R  odds ratio; other abbreviations as in Table 1.STE ACS trial populations (12). Trials of antithrombin
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Blood Transfusions in Non–ST-Segment Elevation ACS October 18, 2005:1490–5herapy for NSTE ACS report transfusion rates of 1% to 5%
16–19), trials of glycoprotein IIb/IIIa inhibitors report
ransfusion rates of 4% to 9% (20,21), and a pooled NSTE
CS trial population reported a transfusion rate of 2.7%
12). Higher transfusion rates in the CRUSADE initiative
ay be due to a greater incidence of patient comorbidities
ompared with trial populations. For example, older age,
enal dysfunction, and presenting CHF are known to be
ore common in community populations than in trial
opulations because of trial exclusions and lower elderly
epresentation in trials (22). Accordingly, each of these
actors was found in our study to be a major predictor of the
eed for transfusion (Table 2). The overlap between pre-
ictors of transfusion and predictors of major bleeding
alidate the association of transfusion as a marker of
receding bleeding events (9,11). In the Global Registry of
cute Coronary Events (GRACE) population, the predic-
ors of bleeding in NSTE ACS also were found to be age,
emale gender, renal insufficiency, blood pressure, and
reatments for heart failure (9), which are similar to the risk
actors for transfusion identified in our population. In
ddition to higher comorbidity-related risks for bleeding in
community population, these risks overlap with treatment
actors. For example, although younger patients can receive
ultiple antithrombotic agents without increasing their
verall risk of transfusion, the risks increase substantially
hen three or more agents are given to elderly patients (age
75 years). Thus, patient and treatment factors both
ontribute to observed risk of bleeding and transfusion.
The common feature of these overlapping major predic-
ors of bleeding and transfusion is their association with the
harmacokinetics and pharmacodynamics of antithrombotic
herapy. Older, smaller patients with renal insufficiency have
ower creatinine clearance. Antithrombotic therapy is dose-
djusted on the basis of patient weight and renal function.
he relationship among patients age 75 years, the use of
hree or more antithrombotic agents, and an increased
ransfusion rate also supports the association between trans-
usion need and patient factors related to antithrombotic
herapy. Although drug dosing data are not available in this
opulation, this association raises the possibility that a
ailure to adjust dosing may be a causative and potentially
odifiable factor.
Interhospital variation in the use of transfusion in this
tudy was greater in magnitude than any differences ob-
erved between transfusion in community and trial popula-
ions. Although some CRUSADE hospitals have low trans-
Table 3. In-Hospital Death and Myocardial In
Outcomes
Blood
Transfusion (%)
No B
Transfu
Death 11.5 3
Death or MI 13.4 5
Determined using non-CABG subpopulation. *Adjusted usi
Abbreviations as in Tables 1 and 2.usion rates (5%), one-quarter of the hospitals in our study transfused more than 20% of their NSTE ACS population.
ome potential explanations include local differences in the
se of drugs and interventions, differences in patient popu-
ations at the site level, or differing local transfusion practice.
owever, clustering of patient characteristics at the hospital
evel was considered in the adjustment, and variation in
ransfusion rates was observed even among centers with
imilar use of revascularization and antithrombotic agents
data not shown). Thus, in the absence of clear guidelines
n transfusion thresholds in NSTE ACS, local transfusion
ractice remains a potential contributor to this observed
ariation. Further exploration into practice patterns that
nfluence bleeding and transfusion thresholds during NSTE
CS is warranted.
ransfusion and outcomes. Our study demonstrates an
ssociation between transfusion and adverse outcomes in an
STE ACS population. The unadjusted rates of death and
composite of death and MI among transfused patients are
hree-fold higher and persist after adjustment. In large part,
his rate may be because patients who receive transfusions
re at higher risk and sicker at baseline. We controlled for
dentifiable clinical factors with use of adjustment, yet
atients who undergo transfusion continued to have a
igher likelihood of dying. Transfusions often are in re-
ponse to bleeding events, which themselves add risk. In the
RACE population, patients who experienced a major
leeding event had three times higher rate of mortality than
hose without bleeding events (18.6% vs. 5.1%) (9). Thus,
leeding events may further explain excess mortality in the
ransfused population. Finally, the safety of transfusion itself
n NSTE ACS is increasingly controversial. Rao et al. (11)
emonstrated in trial populations that blood transfusion was
ssociated with worse survival when given to patients with
adir hematocrits 25%. Sabatine et al. (12) further dem-
nstrated in NSTE ACS trial populations that transfusions
ere associated with more recurrent ischemia and worse
urvival across all hemoglobin levels.
For comparison, the median nadir hematocrit value in our
opulation of those who received a transfusion was 26%. In
ontrast, Wu et al. (10) demonstrated in a community
opulation with acute MI that blood transfusion had a
eneficial effect on survival when hematocrit was 30%.
lthough blood transfusions increase oxygen-carrying ca-
acity and restore plasma volume, adverse consequences
nclude exposure to viral pathogens, immune reactions,
xpansion of blood volume, and increased blood viscosity
23). Stored blood also may promote vasoconstriction and
ion by Transfusion Status
(%)
Unadjusted Risk
OR (95% CI)
Adjusted Risk
OR (95% CI)*
2.96 (2.62–3.35) 1.67 (1.48–1.88)
2.27 (2.06–2.51) 1.44 (1.30–1.60)
CRUSADE clinical model.farct
lood
sion
.8
.8rigger ischemic events (24). Thus, the use of transfusions
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October 18, 2005:1490–5 Blood Transfusions in Non–ST-Segment Elevation ACSbove some threshold in local practice may contribute to
dverse outcomes among transfused patients. Although only
randomized trial of transfusion in a NSTE ACS popula-
ion would clarify the independent effect of transfusion on
utcomes, or its applicable thresholds, observational data
uch as those in this analysis help identify concerns related
o transfusion in community practice.
tudy limitations. We collected transfusion, rather than
ctual bleeding events, because these events are poorly
eported in medical records and difficult to capture via chart
eview in an observational study. The timing of transfusion
n relation to therapeutic interventions and bleeding events
hus could not be determined. As is the case in any
bservational study, the influence of confounding factors on
utcomes between groups is likely to persist despite adjust-
ent. However, these limitations did not devalue our
rimary goal of demonstrating variation in use of transfu-
ion across community practice and its associated risk in
ommunity NSTE ACS populations.
onclusions. Our study highlights that blood transfusion
s common during management of NSTE ACS. Patients
ho undergo a transfusion are at high baseline risk and
xperience worse outcomes after adjustment compared with
ontransfused patients. With increasing use of antithrom-
otic therapy and an aging population, the potential for an
ncrease in transfusion over time is substantial. Although
ause and effect between transfusion and outcomes could
ot be determined in our study, every effort should be made
o minimize the likelihood of transfusion through careful
osing of adjustable anticoagulants and management of
atients during invasive procedures. Furthermore, the wide
ariation found in transfusion practice across centers em-
hasizes that indications for its use in the care of NSTE
CS patients need further clarification.
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